<DOC>
	<DOC>NCT02271204</DOC>
	<brief_summary>This observational study assess the safety of intravenous Ibandronate (Bonviva) intermittent administration in patients with postmenopausal osteoporosis and the efficacy of IV Ibandronate (Bonviva treatment through relative lumbar spine and hip bone mineral densitometry form baseline at year 1)</brief_summary>
	<brief_title>Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>Patients had post menopausal osteoporosis Patients had no contraindication for bisphosphonates Patients had been naive for ibandronate therapy Patients who have signed informed consent and are willing to share their data for data analysis Is not Ibandronate na√Øve Hypersensitivity to any component of the bisphosphonates Ibandronate; Administration of any investigational drug within 30 days preceding the first dose of the study drug.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>